Contrarily, PUMA‐KD tumors displayed weaker growth suppression subsequent to trastuzumab supplementation in comparison with parental cancers (Fig. 5A), suggesting that PUMA shortage eliminated trastuzumab‐mediated counteraction of malignancy. The gene discussed is BBC3; the disease is cancer.